Unicycive Therapeutics Reports Q3 2026 Results, $59 Million in Cash and Securities
Unicycive Therapeutics reported a third-quarter 2026 net loss of $7.0 million, or $0.25 per share, and had approximately $59 million in cash, cash equivalents and marketable securities at September 30. The company said its cash runway is expected to extend beyond 2027, including anticipated costs f…